Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
ODOMZO® (sonidegib) | Efficacy Data
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
![PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/31979901b045184c8053075e4956319c5588d33c/4-Table1-1.png "PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar")
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
Study 1104 Overall Response Rate: R/R MCL | IMBRUVICA® (ibrutinib) HCP
Pecoma Clinical Trial Efficacy Data | FYARRO | HCP Site
Durable Response Rate
Durable Response Rate
Best Overall Response Rate to Treatment | Download Table
Confirmed ORR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Best Overall Response Rate (full analysis population) | Download Table
The overall response rate | Download Table
Confirmed ORR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Efficacy - Overall Response Rate | Aliqopa US HCP
Efficacy endpoints in Oncology
Overall response rate | Download Table
Overall Response Rate of 76% in Advanced Melanoma Patients
Durable Responses Are Observed With Cemiplimab in mBCC
Response Rates for Waldenström Macroglobulinemia Improve With Use of New First-Line, Better-Tolerated Treatments - U.S. Medicine
TECARTUS® Efficacy - Response Data for R/R MCL
Efficacy Data: Overall Response Rate | VITRAKVI® (larotrectinib)
ORR (Objective Response Rate) and related statistics – Part 1
![PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/31979901b045184c8053075e4956319c5588d33c/7-Figure1-1.png "PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar")